[{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"71c0a42c-6796-493e-910c-e7f74252415b","acronym":"CLN-619-001","url":"https://clinicaltrials.gov/study/NCT05117476","created_at":"2022-05-06T19:54:01.352Z","updated_at":"2025-02-25T17:01:30.662Z","phase":"Phase 1","brief_title":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT05117476 - CLN-619-001","lead_sponsor":"Cullinan Therapeutics Inc.","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CLN-619"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-03"},{"id":"0e047eba-7fdc-4c6c-becf-f4667bf4c953","acronym":"","url":"https://clinicaltrials.gov/study/NCT06415487","created_at":"2024-05-15T20:33:36.404Z","updated_at":"2024-07-02T16:35:03.643Z","phase":"Phase 1","brief_title":"ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)","source_id_and_acronym":"NCT06415487","lead_sponsor":"Acepodia Biotech, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/18/2026","primary_completion_date":" 12/18/2026","study_txt":" Completion: 03/25/2027","study_completion_date":" 03/25/2027","last_update_posted":"2024-05-15"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"9a59caa8-c59f-4259-8127-f97b9ad829c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06193486","created_at":"2024-01-05T16:18:01.598Z","updated_at":"2024-07-02T16:35:14.838Z","phase":"Phase 1","brief_title":"Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC","source_id_and_acronym":"NCT06193486","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PSCA","pipe":"","alterations":" ","tags":["PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 01/13/2029","primary_completion_date":" 01/13/2029","study_txt":" Completion: 12/13/2033","study_completion_date":" 12/13/2033","last_update_posted":"2024-03-13"},{"id":"2fb170a4-c1bb-478b-9a26-3efad1e342ff","acronym":"ARYA-2","url":"https://clinicaltrials.gov/study/NCT04634357","created_at":"2022-04-24T10:00:30.724Z","updated_at":"2024-07-02T16:35:15.791Z","phase":"Phase 1/2","brief_title":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT04634357 - ARYA-2","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ET140203"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-03-07"},{"id":"3a9311ae-a132-48fd-ac56-acb0fa708ff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05653271","created_at":"2022-12-16T15:58:33.900Z","updated_at":"2024-07-02T16:35:17.539Z","phase":"Phase 1","brief_title":"ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies","source_id_and_acronym":"NCT05653271","lead_sponsor":"Acepodia Biotech, Inc.","biomarkers":" CD20 • IFNG • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/21/2023","start_date":" 01/21/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-02-28"},{"id":"eb65bd68-98cf-4928-a140-cbe0cd5b48b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06069570","created_at":"2023-10-06T14:11:20.118Z","updated_at":"2024-07-02T16:35:26.093Z","phase":"Phase 1","brief_title":"Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC","source_id_and_acronym":"NCT06069570","lead_sponsor":"Kiromic BioPharma Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • KRAS • BRAF • ALK • ROS1"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-12-15"},{"id":"40405d19-1efa-4e2a-ab60-cb4a514554f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056752","created_at":"2023-09-28T15:10:43.256Z","updated_at":"2024-07-02T16:35:31.924Z","phase":"Phase 1","brief_title":"QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06056752","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD19 positive","tags":["IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 07/03/2025","primary_completion_date":" 07/03/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2023-10-24"},{"id":"83bf3f91-42eb-4886-94d4-0163b22131aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06092047","created_at":"2023-10-23T20:13:37.204Z","updated_at":"2024-07-02T16:35:32.310Z","phase":"Phase 1","brief_title":"UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.","source_id_and_acronym":"NCT06092047","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 positive","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-10-20"},{"id":"38a37beb-d929-43d0-9890-ba3737cd0325","acronym":"","url":"https://clinicaltrials.gov/study/NCT06018363","created_at":"2023-08-30T14:09:03.022Z","updated_at":"2024-07-02T16:35:38.641Z","phase":"Phase 1/2","brief_title":"Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection","source_id_and_acronym":"NCT06018363","lead_sponsor":"Dushu Lake Hospital Affiliated to Soochow University","biomarkers":" IL6 • CD276 • IL10","pipe":" | ","alterations":" CD276 expression","tags":["IL6 • CD276 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QH104"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-30"},{"id":"43102ae6-d1ea-4271-9690-90fe3e1581ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731219","created_at":"2023-02-16T15:00:35.996Z","updated_at":"2024-07-02T16:35:55.393Z","phase":"Phase 1","brief_title":"UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05731219","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2025","study_completion_date":" 09/26/2025","last_update_posted":"2023-02-16"},{"id":"ecf3418c-bacc-4bfa-8dfc-631284d39661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722171","created_at":"2023-02-10T15:00:14.965Z","updated_at":"2024-07-02T16:35:55.834Z","phase":"Phase 1","brief_title":"Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05722171","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2023-02-10"},{"id":"36904a75-f741-450d-9b76-d54c8646a8f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04688853","created_at":"2021-01-19T20:48:13.386Z","updated_at":"2024-07-02T16:36:04.274Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients","source_id_and_acronym":"NCT04688853","lead_sponsor":"Gadeta B.V.","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GDT002"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-09-08"},{"id":"c89e4f6e-89dc-462f-b9c4-dad107cbf4e2","acronym":"ANGELICA","url":"https://clinicaltrials.gov/study/NCT05302037","created_at":"2022-03-31T18:52:43.718Z","updated_at":"2024-07-02T16:36:14.486Z","phase":"Phase 1","brief_title":"Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers","source_id_and_acronym":"NCT05302037 - ANGELICA","lead_sponsor":"CytoMed Therapeutics Pte Ltd","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTM-N2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-31"},{"id":"dbbe31a7-e955-4a0a-8dcd-5eb1bc91b383","acronym":"","url":"https://clinicaltrials.gov/study/NCT03888859","created_at":"2021-01-18T19:09:34.497Z","updated_at":"2024-07-02T16:36:32.648Z","phase":"Phase 1","brief_title":"ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma","source_id_and_acronym":"NCT03888859","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ET1402L1-ARTEMIS T cells"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 04/13/2019","primary_completion_date":" 04/13/2019","study_txt":" Completion: 12/08/2020","study_completion_date":" 12/08/2020","last_update_posted":"2021-03-29"},{"id":"1041c05e-29a6-455b-9723-ee6ca103e007","acronym":"","url":"https://clinicaltrials.gov/study/NCT04702841","created_at":"2021-01-19T20:50:56.628Z","updated_at":"2024-07-02T16:36:33.640Z","phase":"Phase 1","brief_title":"CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors","source_id_and_acronym":"NCT04702841","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA07 • γδT Cell infusion • γδT Cell infusion agent"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-03-08"},{"id":"3e9f16ba-7ef3-4a62-bda2-2d123d6d52a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965546","created_at":"2021-01-18T19:30:34.813Z","updated_at":"2024-07-02T16:36:57.170Z","phase":"Phase 1","brief_title":"ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer","source_id_and_acronym":"NCT03965546","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10","pipe":" | ","alterations":" HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • ET1402L1-ARTEMIS T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 27","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-08-08"},{"id":"856ad1d8-bfdb-472d-854a-1ee9dbe97a1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656147","created_at":"2021-01-18T12:55:28.090Z","updated_at":"2024-07-02T16:37:18.182Z","phase":"Phase 1","brief_title":"Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL","source_id_and_acronym":"NCT02656147","lead_sponsor":"Beijing Doing Biomedical Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gamma delta T-cells • anti-CD19-CAR γδT"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2017","start_date":" 10/01/2017","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2017-09-05"}]